|
Lewis L. Lanier, Ph.D.
Professor
University of California San Francisco
Department Microbiology and Immunology
Dept. of Microbiology & Immunology
|
Education:
Ph.D. |
Microbiology and Immunology, University of North
Carolina -Chapel Hill, 1978 |
B.S. |
Biology (Microbiology), graduated with High Honors, Virginia
Polytechnic Institute and State University, 1975 |
|
Experience:
Vice Chair, Department of Microbiology and Immunology,
University of California San Francisco, 2003-present
Professor, Department of Microbiology and Immunology and the Cancer
Research Institute, University of California San Francisco, 1999-present
Director, Department of Immunobiology, DNAX Research Institute
for Molecular and Cellular Biology, 1997-1999
Associate Director, Department of Human Immunology, DNAX Research
Institute for Molecular and Cellular Biology, 1993-1996
Senior Scientist, Department of Immunology, DNAX Research Institute
for Molecular and Cellular Biology, Inc., 1991-1993
Becton Dickinson Research Fellow and Associate Research Director,
Becton Dickinson Immunocytometry Systems, 1990-1991
Associate Research Director, Becton Dickinson Immunocytometry
Systems, l988-1991
Senior Research Scientist, Becton Dickinson Monoclonal Center,
Inc., 1981-1988
Research Assistant Professor, Department of Pathology, University
of New Mexico School of Medicine, 1981
Postdoctoral Fellow, supported by Damon Runyon-Walter Winchell
Cancer Fund, University of New Mexico School of Medicine, Department
of Pathology, 1979-1981
Postdoctoral Fellow, supported by NIH Training Grant, University
of North Carolina Cancer Research Center at Chapel Hill, 1978-1979
|
Selected publications (recent 5 years)
265. |
Lanier, L.L. and A. Aderem. 2002. Innate Immunity.
Curr. Opin. Immunol. 14:85-86. |
266. |
Masuda, H., Y. Saeki, M. Nomura, K. Shida, M. Matsumoto,
M. Ui, L.L. Lanier, and T. Seya. 2002. High levels of RAE-1
isoforms on mouse tumor cell lines assessed by anti-'pan'
RAE-1 antibody confer tumor susceptibility to NK cells. Biochem.
Biophys. Res. Commun. 290:140-145. |
267. |
Cerwenka, A., C.A. O'Callaghan, J.A. Hamerman, R. Yadav,
W. Ajayi, D.C. Roopenian, S. Joyce, and L.L. Lanier. 2002.
Cutting Edge: The minor histocompatibility antigen H60 peptide
interacts with both H-2Kb and NKG2D.
J. Immunol. 168:3131-3134. |
268. |
Naper, C., S. Hayashi, L. Kveberg, E.C. Niemi, L.L. Lanier,
J.T. Vaage, and J.C. Ryan. 2002. Ly-49s3 is a promiscuous
activating rat NK cell receptor for nonclassical MHC class
I-encoded target ligands. J. Immunol. 169:22-30. |
269. |
Arase, H., and L.L. Lanier. 2002. Viral-driven evolution
of natural killer cell receptors. Microbes Infect. 4:1505-1512. |
270. |
Arase, H., E.S. Mocarski, A.E. Campbell, A.B. Hill, and
L.L. Lanier. 2002. Direct recognition of cytomegalovirus by
activating and inhibitory NK cell receptors. Science 296:1323-1326. |
271. |
Ogasawara, K., S.K. Yoshinaga, and L.L. Lanier. 2002. Inducible
costimulator costimulates cytotoxic activity and IFN- production
in activated murine NK cells. J. Immunol. 169:3676-3685. |
272. |
Lodoen, M., K. Ogasawara, J.A. Hamerman, H. Arase, J.P.
Houchins, E.S. Mocarski, and L.L. Lanier. 2003. NKG2D-mediated
natural killer cell protection against cytomegalovirus is
impaired by viral gp40 modulation of retinoic acid early inducible
1 gene molecules. J. Exp. Med. 197:1245-1253. |
273. |
Michaelsson, J., C. Teixeira de Matos, A. Achour, L.L. Lanier,
K. Karre, and K. Soderstrom. 2002. A signal peptide derived
from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition.
J. Exp. Med. 196:1403-1414. |
274. |
Ogasawara, K., J.A. Hamerman, H. Hsin, S. Chikuma, H. Bour-Jordon,
T. Chen, T. Pertel, C. Carnaud, J.A. Bluestone and L.L. Lanier.
2003. Impairment of NK cell function by NKG2D modulation in
NOD mice. Immunity 18:41-51. |
275. |
Lanier, L.L. 2003. Natural killer cell receptor signaling.
Curr. Opin. Immunol. 15:308-314. |
276. |
Cerwenka, A., and L.L. Lanier. 2003. NKG2D ligands: unconventional
MHC class I-like molecules exploited by viruses and cancer.
Tissue Antigens 61:335-343. |
277. |
Westgaard, I.H., E. Dissen, K.M. Torgensen, S. Lazetic,
L.L. Lanier, J.H. Phillips, and S. Fossum. 2003. The lectin-like
receptor KLRE1 inhibits natural killer cell cytotoxicity.
J. Exp. Med. 197:1551-1561. |
278. |
Wu, J., and L.L. Lanier. 2003. NK cells and cancer. Adv.
Cancer Research 90:127-156. |
279. |
Humphrey, M.B., K. Ogasawara, W. Yao, S.C. Spusta, M.R.
Daws, N.E. Lane, L.L. Lanier, and M.C. Nakamura. 2004. The
signaling adapter protein DAP12 regulates multinucleation
during osteoclast development. J. Bone Miner. Res. 19:224-234. |
280. |
Zompi, S., J.A. Hamerman, K. Ogasawara, E. Schweighoffer,
V.L.J. Tybulewicz, J.P. DiSanto, L.L. Lanier, and F. Colucci.
2003. NKG2D triggers cytotoxicity in mouse NK cells lacking
DAP12 or Syk family kinases. Nat. Immunol. 4:565-572. |
281. |
Arase, H. and L.L. Lanier. 2004. Specific recognition of
virus-infected cells by paired NK receptors. Rev. Med. Virol.
14:83-93. |
282. |
Hamerman, J.A., K. Ogasawara, and L.L. Lanier. 2004. Cutting
Edge: Toll-like receptor signaling in macrophages induces
ligands for the NKG2D receptor. J. Immunol. 172:2001-2005. |
283. |
Shiratori, I., K. Ogasawara, T. Saito, L.L. Lanier, and
H. Arase. 2004. Activation of natural killer cells and dendritic
cells upon recognition of a novel CD99-like ligand by paired
immunoglobulin-like type 2 receptor. J. Exp. Med. 199:525-533. |
284. |
Lanier. L.L. 2005. Human NK Receptors and their MHC Ligands.
In: HLA 2004: Immunobiology of the Human MHC. Proceedings
of the 13th International Histocompatibility Workshop and
Conference, Seattle, WA: IHWG Press, J Hansen and B Dupont,
Eds. In press. |
285. |
Rosen, D.B. M. Araki, J.A. Hamerman, T. Chen, T. Yamamura,
and L.L. Lanier. 2004. A structural basis for the association
of DAP12 with mouse, but not human, NKG2D. J. Immunol. 173:2470-2478. |
286. |
Tahara-Hanaoka, S., K. Shibuya, Y. Onoda, H. Zhang, S. Yamazaki,
A. Miyamoto, S-I. Honda, L.L. Lanier, and A. Shibuya. 2004.
Functional characterization of DNAM-1 (CD226) interaction
with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Int.
Immunol. 16:533-538. |
287. |
Lanier, L.L. 2005. NKG2D in innate and adaptive immunity.
Adv. Exp. Med. Biol. 560:51-56. |
288. |
Trinchieri, G. and L.L. Lanier. 2005. Functions of Natural
Killer cells. In: Williams' Hematology 7th Ed., E. Beutler
et al. ed., McGraw Hill, Chapter 79, p. 1077-1082. |
289. |
Mócsai, A., M.B. Humphrey, J.A.G. Van Ziffle, Y.
Hu, A. Burghardt, S.C. Spusta, S. Majumdar, L.L. Lanier, C.A.
Lowell, and M.C. Nakamura. 2004. The immunomodulatory adapter
proteins DAP12 and Fc receptor γ-chain (FcR) regulate
development of functional osteoclasts through the Syk tyrosine
kinase. Proc. Natl. Acad. Sci. USA, 101:6158-6163. |
290. |
Ogasawara, K., J.A. Hamerman, L.R. Ehrlich, H. Bour-Jordon,
P. Santamaria, J.A. Bluestone, and L.L. Lanier. 2004. NKG2D
blockade prevents autoimmune diabetes in NOD mice. Immunity
20:757-767. |
291. |
Lanier, L.L. 2004. NKG2D. J. Biol. Regul. Homeost. Agents
17:338-340. |
292. |
Zingoni, A., T. Sornasse, B.G. Cocks, Y. Tanaka, A. Santoni,
and L.L. Lanier. 2005. NK cell regulation of T cell-mediated
responses. Mol. Immunol. 42:451-454. |
293. |
Takaki, R., and L.L. Lanier. 2005. Immune surveillance in
cancer. In: Viral and Immunological Malignancies, P.A. Volberding
and J. Palefsky, eds. BC Decker Inc. Publisher, Hamilton,
Ontario, Canada, Chapter 3. |
294. |
Zingoni, A., T. Sornasse, B.G. Cocks, Y. Tanaka, A. Santoni,
and L.L. Lanier. 2004. Cross-talk between activated human
NK cells and CD4+ T cells via OX40-OX40
ligand interactions. J. Immunol. 173:3716-3724. |
295. |
Lodoen, M.B. and L.L. Lanier. 2005. Viral modulation of
NK cell immunity. Nat. Rev. Microbiol. 3:59-69. |
296. |
Meresse, B., Z. Chen, C. Ciszewski, M. Tretiakova, G. Bhagut,
T.N. Krausz, D.H. Raulet, L.L. Lanier, V. Groh, T. Spies,
E.C. Ebert, P.H. Green, and B. Jabri. 2004. Coordinated induction
by IL15 of a TCR-independent NKG2D signaling pathway converts
CTL into lymphokine-activated killer cells in celiac disease.
Immunity 21:357-366. |
297. |
Voehringer, D., D.B. Rosen, L.L. Lanier, and R.M. Locksley.
2004. CD200 receptor family members represent novel DAP12-associated
activating receptors on basophils and mast cells. J. Biol.
Chem. 279:54117-54123. |
298. |
Hamerman, J.A., K. Ogasawara, and L.L. Lanier. 2005. NK
cells in innate immunity. Curr. Opin. Immunol. 17:29-35. |
299. |
Lodoen, M.B., G. Abenes, S. Umamoto, J.P. Houchins, F. Liu,
and L.L. Lanier. 2004. The cytomegalovirus m155 gene product
subverts natural killer cell antiviral protection by disruption
of H60-NKG2D interactions. J. Exp. Med. 200:1075-1081. |
300. |
Lanier, L.L. 2005. NK cell recognition. Annu. Review Immunol.
23:225-274. |
301. |
Richie Ehrlich, L.I., K. Ogasawara, J.A. Hamerman, R. Takaki,
A. Zingoni, J.P. Allison, and L.L. Lanier. 2005. Engagement
of NKG2D by cognate ligand or antibody alone is insufficient
to mediate costimulation of human and mouse CD8+
T cells. J. Immunol. 174:1922-1931. |
302. |
Bach, J-F., A. Bendelac, M.B. Brenner, H. Cantor, G. De
Libero, M. Kronenberg, L.L. Lanier, D.H. Raulet, M.J. Shlomchik,
and M.G. von Herrath. 2004. The role of innate immunity in
autoimmunity. J. Exp. Med. 200:1527-1531. |
303. |
Lanier, L.L. 2005. First sighting of the elusive T cell
antigen receptor. J. Immunol. 174:1143. |
304. |
Hamerman, J.A., N. K. Tchao, C.A. Lowell, and L.L. Lanier.
2005. Enhanced Toll-like receptor responses in the absence
of signaling adaptor DAP12. Nat. Immunol. 6:579-586. |
305. |
Lanier, L.L. 2005. Missing self, NK cells and the White
Album. J. Immunol. 174:6565. |
306. |
Desrosiers, M-P., A. Kielczewska, J-C. Loredo-Osti, S.G.
Adam, A.P. Makrigiannis, S. Lemieux, T. Pham, M.B. Lodoen,
K. Morgan, L.L. Lanier, and S.M. Vidal. 2005. Epistasis between
Klra and major histocompatibility complex class I loci is
associated with a new mechanism of natural killer cell-mediated
innate resistance to cytomegalovirus infection. Nat. Genet.
37:593-599. |
307. |
Vidal. S.M., and L.L. Lanier. 2005. NK cell recognition
of mouse cytomegalovirus-infected cells. Current Topics in
Microbiology and Immunology 298:183-206. |
308. |
Takaki, R., Y. Hayakawa, A. Nelson, P.V. Sivakumar, S. Hughes,
M.J. Smyth, and L.L. Lanier. 2005. IL-21 enhances tumor rejection
through a NKG2D-dependent mechanism. J. Immunol. 175:2167-2173. |
309. |
Humphrey, M.B., L.L. Lanier, and M.C. Nakamura. 2005. Role
of ITAM-containing adapter proteins and their receptors in
the immune system and bone. Immunol. Rev. 208:50-65. |
310. |
Shiratori, I., M. Tamaguchi, M. Suzukawa, K. Yamamoto, L.L.
Lanier, T. Saito, and H. Arase. 2005. Down-regulation of basophil
function by human CD200 and human herpesvirus-8 CD200. J.
Immunol. 175:4441-4449. |
311. |
Ogasawara, K., J. Benjamin, R. Takaki, J.H. Phillips, and
L.L. Lanier. 2005. Function of NKG2D in natural killer cell-mediated
rejection of mouse bone marrow grafts. Nat. Immunol. 6:938-945. |
312. |
Hamerman, J.A. and L.L. Lanier. 2006. Inhibition of immune
responses by ITAM-bearing receptors. Science STKE volume 2006,
issue 320, pp. re1. |
313. |
Rosen, D.B., J. Bettadapura, M. Alsharifi, P.A. Mathew,
H.S. Warren, and L.L. Lanier. 2005. Cutting Edge: Lectin-like
transcript-1 is a ligand for the inhibitory human NKR-P1A
receptor. J. Immunol. 175:7796-7799. |
314. |
Ogasawara, K. and L.L. Lanier. 2005. NKG2D in NK and T cell-mediated
immunity. J. Clin. Immunol. 25:534-540. |
315. |
Humphrey, M.B., M.R. Daws, S.C. Spusta, E.C. Niemi, J.A.
Torchia, L.L. Lanier, W.E. Seaman, and M.C. Nakamura. 2006.
TREM2, a DAP12-associated receptor, regulates osteoclast differentiation
and function. J. Bone Mineral Research 21:237-245. |
316. |
Routes, J.M., S. Ryan, K. Morris, R. Takaki, A. Cerwenka,
and L.L. Lanier. 2005. Adenovirus serotype 5 E1A sensitizes
tumor cells to NKG2D-dependent NK cell lysis and tumor rejection.
J. Exp. Med. 202:1477-1482. |
317. |
Chen, S., H. Kawashima, J.B. Lowe, L.L. Lanier, and M. Fukuda.
2005. Suppression of tumor formation in lymph nodes by L-selectin-mediated
natural killer cell recruitment. J. Exp. Med. 202:1679-1689. |
318. |
Bui, J.D., L.N. Carayannopoulos, L.L. Lanier, W.M. Yokoyama,
and R.D. Schreiber. 2006. Interferon-dependent downregulation
of the NKG2D-ligand H60 on tumors. J. Immunol. 176:905-913. |
319. |
Chan, C., E. Crafton, H-N., Fan, K. Yoshimura, J. Flook,
D. Brockstedt, T.W. Dubensky, M.F. Stins, L.L. Lanier, D.M.
Pardoll, and F. Housseau. 2006. Innate killer-dendritic cells
directly link innate and adaptive immunity. Nature Medicine
12:207-213. |
320. |
Hesslein, D.G.T., R. Takaki, M.L. Hermiston, A. Weiss, and
L.L. Lanier. 2006. Dysregulation of signaling pathways in
CD45-deficient NK cells leads to differentially regulated
cytotoxicity and cytokine production. Proc. Natl. Acad. Sci.
USA 103:7012-7017. |
321. |
Lodoen, M. and L.L. Lanier. 2006. NK cells as an initial
defense against pathogens. Curr. Opin. Immunol., In press. |
322. |
Shiow, L.R., D.B. Rosen, N. Brdickova, Y. Xu, J. An, L.L.
Lanier, J.G. Cyster, and M. Matloubian. 2006. CD69 acts downstream
of interferon-α/β to inhibit S1P1 and lymphocyte egress from
lymphoid organs. Nature 440:540-544. |
323. |
Cao, W., D.B. Rosen, T. Ito, L. Bover, M. Bao, G. Watanabe,
L. Zhang, L.L. Lanier, and Y-J. Liu. 2006. Plasmacytoid dendritic
cell-specific receptor ILT7/FcεRIγ inhibits Toll-like receptor-induced
interferon production. J. Exp. Med. 203:1399-1405. |
324. |
Lanier, L.L. 2006. Viral immunoreceptor tyrosine-based activation
motif (ITAM)-mediated signaling in cell transformation and
cancer. Trends in Cell Biology, In press. |
325.
|
Meresse, B., S.A. Curran, C. Ciszewski, G. Orbelyan, M.
Setty, G. Bhagat, L. Lee, M. Tretiakova, C. Semrad, E. Kistner,
R.J. Winchester, V. Braud, L.L. Lanier, D.E. Geraghty, P.H.
Green, S. Guandalini, and B. Jabri. 2006. Reprogramming of
CTLs into natural killer-like cells in celiac disease. J.
Exp. Med. 203:1343-1355. |
326. |
Hamerman, J.A., J.R. Jarjoura, M.B. Humphrey, M.C. Nakamura,
W.E. Seaman, and L.L. Lanier. 2006. Cutting Edge: Inhibition
of Toll-like receptor and Fc-receptor responses in macrophages
by TREM-2 and DAP12. J. Immunol., In press. |
|
|